Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Taurine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Taurine. Displaying page 1 of 1.
    EudraCT Number: 2005-000680-26 Sponsor Protocol Number: Taurine05 Start Date*: 2005-06-27
    Sponsor Name:North west London Hospital Trust
    Full Title: A randomised double blind controlled crossover trial of intravenous taurine supplementation in parenteral nutrition as an effective treatment for reducing hepatobiliary complications in chronic int...
    Medical condition: Complications of intravenous nutrition include cholestatic liver disease. This is one of the main causes of death during long-term home parenteral nutrition (HPN) and a study in 2000 found that 65%...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004196-37 Sponsor Protocol Number: PA02-124 1 RO1AT002146-01 Start Date*: 2006-09-22
    Sponsor Name:University of Birmingham, Research & Enterprise Services [...]
    1. University of Birmingham, Research & Enterprise Services
    2. Heart of England NHS Foundation Trust Birmingham Heartlands Hospital
    Full Title: Taurine and Painful Diabetic Neuropathy
    Medical condition: Diabetic painful peripheral neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002329-56 Sponsor Protocol Number: FISIO Start Date*: 2021-10-19
    Sponsor Name:Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)
    Full Title: Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical...
    Medical condition: Acquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077255 Intensive care unit acquired weakness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012602-39 Sponsor Protocol Number: 05-NEOV-002 Start Date*: 2010-05-17
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study evaluating the safety, tolerability, protein accretion, amino acid plasma levels and long-term outcome of Neoven compared to Vaminolact(R) in premature very low bir...
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for premature ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051284 Parenteral nutrition LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012604-92 Sponsor Protocol Number: 05-NEOV-004 Start Date*: 2010-04-19
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study of the safety and efficacy of Neoven compared to Vaminolact in infants and children requiring long-term parenteral nutrition
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for infants an...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051284 Parenteral nutrition LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012603-26 Sponsor Protocol Number: 05-NEOV-003 Start Date*: 2010-04-08
    Sponsor Name:Fresenius Kabi Deutschland GmbH [...]
    1. Fresenius Kabi Deutschland GmbH
    2. Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for premature ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051284 Parenteral nutrition LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000429-20 Sponsor Protocol Number: 05-NEOV-001 Start Date*: 2008-10-17
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051284 Parenteral nutrition LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009918-40 Sponsor Protocol Number: LG-TAU-2008-04 Start Date*: 2009-07-22
    Sponsor Name:LABORATORIOS GRIFOLS, S.A.
    Full Title: Ensayo Clínico fase IV, prospectivo, aleatorizado, doble ciego, de grupos paralelos y unicéntrico, para evaluar el efecto de la taurina en Nutrición Parenteral Total sobre la función hepática en pa...
    Medical condition: Evaluar el efecto de la taurina en nutrición Parenteral Total sobre la función hepática en pacientes postquirúrgicos. Evaluate the effect of taurine in Total Parenteral Nutrition on the hepatic fun...
    Disease: Version SOC Term Classification Code Term Level
    9 10044107 Total parenteral nutrition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003192-30 Sponsor Protocol Number: CLJN452X2202 Start Date*: 2016-03-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD).
    Medical condition: primary bile acid diarrhea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10032786 Other specified intestinal malabsorption LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000360-17 Sponsor Protocol Number: TGO-VGB-III-01 Start Date*: Information not available in EudraCT
    Sponsor Name:TARGEON
    Full Title: Acceptability study of a new paediatric form of vigabatrin in infants and children with infantile spasms or pharmaco-resistant partial epilepsy. Observational, descriptive, open-label, multi-centr...
    Medical condition: Infantile spasms and pharmaco-resistant partial epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10021750 Infantile spasms PT
    18.0 10029205 - Nervous system disorders 10065336 Partial epilepsy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005795-13 Sponsor Protocol Number: Ketoil 01/07 Start Date*: 2007-11-12
    Sponsor Name:MIPHARM
    Full Title: EFFICACY AND SAFETY ASSESSMENT OF KETOIL, SHAMPOO CONTAINING KETOCONAZOLE 0.5% SERENOA REPENS (SAW PALM) AND TAURINE, IN THE TREATMENT OF PATIENTS AFFECTED BY DANDRUFF AND SEBORRHEIC DERMATITIS COM...
    Medical condition: dandruff and seborroic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050909 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004693-42 Sponsor Protocol Number: 747-206 Start Date*: 2015-06-29
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open Label, Single- and Multiple-Dose, Dose Finding Study to Assess the Effects of Obeticholic Acid in Pediatric Subjects with Biliary Atresia
    Medical condition: Biliary atresia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10004653 Biliary atresia LLT
    20.1 100000004850 10004654 Biliary atresia, congenital LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004946-41 Sponsor Protocol Number: SP-PP18 Start Date*: 2019-09-12
    Sponsor Name:Dr. Virgilio P. Carnielli,
    Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial
    Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition.
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 10:29:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA